A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

This study has been withdrawn prior to enrollment.

Sponsor:

Collaborator:

PDL BioPharma, Inc.

Information provided by:

Facet Biotech

ClinicalTrials.gov Identifier:

NCT00502294

First received: July 13, 2007

Last updated: June 23, 2009

Last verified: July 2008

No Study Results Posted on ClinicalTrials.gov for this Study

Study was withdrawn before participants were enrolled.

Study Status:	This study has been withdrawn prior to enrollment.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given